![](https://images.squarespace-cdn.com/content/v1/54c68ac6e4b06d2e36a4b8c9/1585411667181-4DAUOCOD82BM712P2DRA/image-asset.jpeg)
LATEST NEWS IN PROSTATE CANCER
Xofigo (Radium-223): An Overview
Radium-223 is used to treat bone metastases, a common problem for men living with metastatic hormone resistant prostate cancer (MHRPC), affecting up to 90% of these patients. The development of a drug called radium-223 (brand name: Xofigo) is a substantial innovation, not only because it causes less toxicity compared to its predecessors, but also because it prolongs life.